FDA approves CAR T cell treatment for resistant mantle cell lymphoma

by Jim Stallard,Memorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainMantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatme

Updated on: August 27,2024

FDA approves CAR T cell treatment for resistant mantle cell lymphoma

by Jim Stallard,Memorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainMantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatme

Updated on:August 27,2024

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on: November 02,2023

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on:November 02,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on: October 17,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on:October 17,2023

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on: October 24,2023

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on:October 24,2023

Cost of cancer treatment can impact health of survivors

byMedical College of Georgia at Augusta UniversityDrs. Steven Coughlin, from left, Jorge Cortes and Biplab Datta. Credit: Michael Holahan, Augusta UniversityA significant number of people who ha

Updated on: December 18,2023

Cost of cancer treatment can impact health of survivors

byMedical College of Georgia at Augusta UniversityDrs. Steven Coughlin, from left, Jorge Cortes and Biplab Datta. Credit: Michael Holahan, Augusta UniversityA significant number of people who ha

Updated on:December 18,2023

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on: October 12,2023

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on:October 12,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on: October 24,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on:October 24,2023

New insights into colorectal cancer and E. coli

by Béatrice St-Cyr-Leroux,University of MontrealclbA and bft detection. a clbA and b bft presence in DNA extracted from fecal samples were detected using conventional qualitative PCR. M: marker;

Updated on: December 17,2023

New insights into colorectal cancer and E. coli

by Béatrice St-Cyr-Leroux,University of MontrealclbA and bft detection. a clbA and b bft presence in DNA extracted from fecal samples were detected using conventional qualitative PCR. M: marker;

Updated on:December 17,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on: December 21,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on:December 21,2023

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Updated on: October 15,2023

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Updated on:October 15,2023

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Updated on: December 17,2023

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Updated on:December 17,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on: October 17,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on:October 17,2023